How long does it take to take Apelvis as a targeted drug? Treatment cycle and drug resistance issues

Alpelisib (Alpelisib) is a targeted drug targeting the PI3K (phosphatidylinositol 3-kinase) pathway. It is mainly used to treat Treatment of HRpositive HER2negative metastatic breast cancer with PIK3CA mutations. The treatment cycle of Apelvis is usually determined by the doctor based on the patient's specific condition and treatment response. Generally speaking, apelvis is a long-term drug, and the treatment time may be adjusted based on the patient's tumor progression, drug resistance, and side effects.

Treatment with Apelvis is usually continuous, with patients requiring daily oral medication until the tumor is effectively controlled or significant side effects occur. The duration of treatment depends on a variety of factors, such as the patient's response to the drug, the stability of the condition, and management of side effects. Generally, treatment cycles with Apelvis may last several months or even longer. Patients need regular reexamination during treatment, including imaging examinations and biomarker testing, to evaluate the effect of treatment and decide whether the treatment plan needs to be adjusted.

Although apelvis has significant efficacy in many breast cancer patients with PIK3CA mutations, a subset of patients may develop drug resistance over time. Drug resistance usually manifests as tumor progression or diminished drug response. This may be due to tumor cells adapting to the effects of the drug through genetic mutations or other pathways, making the targeted effect of apelvis no longer effective. To address this issue, researchers are exploring the combination of apelvis with other drugs to enhance the anti-tumor effect and delay the development of drug resistance.

When a patient develops drug resistance, doctors usually evaluate the patient's response to treatment and decide whether the drug needs to be changed or the treatment plan needs to be adjusted. In addition to apelix monotherapy, clinical trials are also exploring combination treatment with other targeted drugs or chemotherapy drugs. For example, apelvis combined with hormone therapy or HER2-targeted therapy may help overcome drug resistance and further control tumors. The patient's treatment plan should be dynamically adjusted based on the development of drug resistance and changes in the condition.

Reference materials:https://www.piqray.com/